Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olive Leaf Extract in Acute Coronary Syndrome
NCT06723002Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Sponsor
- Université de Monastir
- Modality
- Small Molecules
- Drugs
- atherolive
- Conditions
- acute coronary syndrome (ACS)
01
Overview
Phase 3, randomised, double-blind trial of atherolive in acute coronary syndrome (ACS) (3 arms), sponsored by Université de Monastir. Primary endpoint: Reactive Hyperemia Index at 30 days. Planned start Dec 2024; status: not yet recruiting.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Atherolive 500mg/day
250mg twice daily
Atherolive 1000mg/day
500mg twice daily
Placebo
Placebo twice daily
03
Who it enrols
Adult patients with Acute Coronary Syndrome presenting with ST-segment alterations, without severe LV hypertrophy, valvular heart disease, or planned surgery.
04
Endpoints
Primary
Reactive Hyperemia Index
Secondary
Major Adverse Cardiac Events rate
Beyond the preview
Go deeper on NCT06723002.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723002.